Back

TriSalus wins FDA 510(k) clearance for TriNav Advance

Verifying
  • FDA cleared TriSalus Life Sciences’ TriNav Advance for 510(k) marketing authorization.
  • TriSalus shares were up 6.29% at $5.24 at Wednesday publication.
  • TriNav Advance adds access to small, distal vessels through a compatible microcatheter.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.